Hepatogenic weakness as a clinical marker of hyperammonemia and of the effectiveness of its correction in patients with pre-cirrhotic stages of non-alcoholic fatty liver disease
The aim of this work was identification of markers of of hyperammonemia (HA) available in routine practice, and assessment of the effectiveness of ornithine in treatment of HA and its clinical manifestations in patients with NAFLD at the pre-cirrhotic stage.Outpatients with NAFLD with hepatic steato...
Saved in:
| Main Authors: | E. M. Petrova, V. A. Cheraneva, V. G. Grachev |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Open Systems Publication
2021-06-01
|
| Series: | Лечащий Врач |
| Subjects: | |
| Online Access: | https://journal.lvrach.ru/jour/article/view/173 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Improvement of non-alcoholic fatty liver disease treatment
by: P. I. Seliverstov, et al.
Published: (2014-10-01) -
CORRECTION OF MICROCIRCULATORY DISORDERS IN NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH CHRONIC HEART FAILURE PATIENTS
by: M. E. Statsenko, et al.
Published: (2016-12-01) -
From cirrhosis to hepatogenous diabetes: risk factors and glycemic management
by: Jing Zhang, et al.
Published: (2024-06-01) -
Sex-specific effect of dietary fatty acids on non-alcoholic fatty liver disease
by: Jianhua Chen, et al.
Published: (2025-07-01) -
Usefulness of pemafibrate for non-alcoholic fatty liver disease with hypertriglyceridemia
by: Masahiro Kikuchi, et al.
Published: (2024-09-01)